DIA
GEVA

Denver Investment Advisors’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Denver Investment Advisors’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-19,974
Closed -$1.85M – 690
2014
Q4 		$1.85M Buy
19,974
+283
+1% +$22.3K 0.06% 285
2014
Q3 		$1.35M Sell
19,691
-152
-0.8% -$10.9K 0.04% 320
2014
Q2 		$2.08M Sell
19,843
-5,596
-22% -$476K 0.06% 293
2014
Q1 		$2.11M Buy
+25,439
New +$2.35M 0.06% 298

Other funds holding GEVA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Denver Investment Advisors's GEVA Position: Q1 2015 in Review

Denver Investment Advisors sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q1 2015, closing a stake of 19,974 shares — an estimated $1.85M sold.

Denver Investment Advisors first reported a position in GEVA in Q1 2014 and held it in 4 quarters. The position peaked at $2.11M in Q1 2014. 130 funds tracked by Wall St. Rank hold GEVA as of Q1 2015.

  • Denver Investment Advisors reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q1 2015 after selling out during the quarter.
  • Denver Investment Advisors sold 19,974 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q1 2015, an estimated $1.85M.
  • Denver Investment Advisors first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q1 2014 and held it in 4 quarters.
  • Denver Investment Advisors's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $2.11M in Q1 2014.
  • 130 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q1 2015.

Based on Denver Investment Advisors's 13F filing for Q1 2015, filed 14 May 2015.